Alcidion Group to Release Q4 FY26 Appendix 4C Cash Flow Report and Host Investor Webcast on 23 July 2026

Alcidion to Publish Q4 FY26 Appendix 4C Quarterly Cash Flow Report on 23 July 2026

Alcidion Group Limited confirmed it will release its Appendix 4C Quarterly Cash Flow Report for the quarter ending 30 June 2026 on Thursday, 23 July 2026. This mandatory ASX reporting document provides shareholders and analysts with transparency on the company’s cash receipts, payments, and liquidity during the period.

As a healthcare software technology company, Alcidion’s quarterly cash flow report is a key indicator of operational health. Investors and analysts will assess cash inflows from customers, staff and administrative expenses, and net operating cash flows to evaluate the company’s progress toward sustainable cash generation. Specific financial details for Q4 FY26 will be disclosed in the formal Appendix 4C release. The immediate market impact of this announcement remains unclear.

CEO Kate Quirke and CFO Matthew Gepp to Present Q4 FY26 Operational and Commercial Highlights

The investor webcast at 11:00am AEST on 23 July 2026 will be led by Group Managing Director and CEO Kate Quirke and CFO Matthew Gepp. They will provide insights into the operational and commercial performance of Q4 FY26, complementing the Appendix 4C data with qualitative context.

The webcast will feature a Q&A session, enabling registered investors to ask questions directly to senior management. Given Alcidion’s presence in specialised healthcare IT markets across multiple countries, questions may cover contract pipeline updates, progress on the Miya Precision platform, and market conditions in the UK and Australasian healthcare systems. Investors are encouraged to submit questions in advance to [email protected] due to time constraints.

Registration Details for Alcidion’s Q4 FY26 Investor Webcast via Zoom

The webcast will be conducted via Zoom webinar. Interested investors and market participants can register using the official Zoom registration link provided in the company’s update. Registered participants will receive a confirmation email with access details, including Zoom links and phone dial-in options, facilitating participation regardless of location or device.

The webcast is open to retail and institutional investors, market analysts, and media. This digital engagement approach aligns with trends among ASX-listed tech companies to provide live, accessible results presentations. While Alcidion has not confirmed post-event recordings or transcripts, investors should monitor official channels for any follow-up materials.

Alcidion’s Miya Precision Platform: Central to Its Healthcare IT Solutions

Alcidion’s flagship product, Miya Precision, is a clinical intelligence platform that consolidates critical patient data into centralized dashboards for healthcare professionals. It supports interoperability between diverse healthcare systems, streamlines communication and task management, and delivers clinical decision support at the point of care. These features align with hospital priorities to reduce clinical risk and enhance patient outcomes.

Miya Precision anchors Alcidion’s portfolio of software products and technical services, forming the basis of its revenue model through software licensing and recurring services to hospitals and healthcare organisations. This model typically generates predictable subscription-style cash flows over multi-year contracts. The upcoming Q4 FY26 Appendix 4C will shed light on the revenue performance and customer receipts from the Miya Precision ecosystem during the quarter ending 30 June 2026.

Alcidion’s Operations Across Australia, New Zealand, and the United Kingdom

Since its ASX listing in 2016, Alcidion has expanded through organic growth and targeted acquisitions, now operating in three key markets: Australia, New Zealand, and the United Kingdom. Each market presents unique healthcare systems, regulatory frameworks, and procurement cycles, requiring localized commercial and implementation capabilities alongside core product development.

The UK market offers significant opportunity given the scale of the National Health Service and its investments in digital health infrastructure. Operating internationally introduces currency risk and cross-border management complexities, factors investors should consider when reviewing quarterly cash flow results. Alcidion has indicated plans for further geographic expansion but has not disclosed specific new markets or timelines. This multi-market footprint distinguishes Alcidion from purely domestic Australian healthcare IT competitors.

Alcidion’s 25-Year Healthcare Technology Experience and Growth Strategy

With over 25 years in healthcare technology, Alcidion leverages deep expertise in clinical workflows, hospital operations, and regulatory compliance. This experience fosters trust and long-term relationships critical in healthcare IT.

The company’s growth strategy includes acquisitions of healthcare IT firms since its 2016 ASX listing, enhancing its product offerings, customer base, and geographic reach. This acquisition-driven model influences its cash flow profile. The Q4 FY26 Appendix 4C will provide insights into how the integrated business is performing financially as it continues to pursue its mission of transforming healthcare with intelligent technology solutions.

Sector Trends Driving Demand for Alcidion’s Clinical Decision Support Solutions

Structural trends such as ageing populations in Australia, New Zealand, and the UK increase pressure on hospital systems, boosting demand for technology that improves efficiency and reduces clinical errors. Government digital health initiatives in these regions create funded procurement opportunities for platforms like Miya Precision.

Interoperability remains a top policy priority, and Miya Precision’s capabilities align well with this need, positioning Alcidion strongly in competitive tenders for hospital and health network contracts. The Q4 FY26 results and webcast will provide investors with insight into how effectively the company is capitalizing on these favorable market conditions.

Risks for Investors to Consider Ahead of the Q4 FY26 Results

Despite strong sector tailwinds, Alcidion faces risks including lengthy and complex healthcare IT procurement cycles, budget constraints, and political factors that may delay contract signings and implementations, potentially impacting quarterly cash receipts.

Operating across three countries exposes the company to foreign exchange fluctuations, particularly between the British pound and Australian dollar, affecting UK revenue and costs. The acquisition growth strategy introduces integration challenges and product portfolio complexity. Additionally, Alcidion competes with global enterprise software vendors and specialised regional players. These risks provide important context for interpreting the upcoming quarterly results.

Implications of the 23 July 2026 Quarterly Update for Alcidion Investors

The Q4 FY26 Appendix 4C release and accompanying investor webcast on 23 July 2026 mark a significant event for shareholders and prospective investors. The fourth quarter often reflects the culmination of sales and renewal cycles, making Q4 cash receipts a key indicator of annual commercial success and pipeline conversion.

Investors will look for commentary from CEO Kate Quirke and CFO Matthew Gepp on contract pipeline status, recurring revenue trends, and expansion plans. The Q&A session offers additional transparency on matters important to shareholders. Together, the Appendix 4C data and management discussion are expected to influence market sentiment on Alcidion’s FY26 full-year performance and outlook for FY27.